Related coverage linked through entity extraction aliases.
May 26, 2026
The FDA granted Breakthrough Device Designation to TOBY Inc.'s urine-based Alzheimer's diagnostic test and Instanosis Inc.'s Xylazine Rapid Test (Urine), accelerating development of both non-invasive diagnostic technologies.
May 18, 2026
People with Down syndrome have a 90% to 95% lifetime risk of Alzheimer’s disease. Amyloid accumulation is almost inevitable by age 40, and baseline assessment is recommended by age 40 with annual follow-up.
Apr 28, 2026
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Apr 20, 2026
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Mar 18, 2026
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Mar 15, 2026
Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.
Mar 03, 2026
Healthcare systems worldwide are addressing polypharmacy as a major public health issue, with new guidance emphasizing person-centered medication reviews and risk mitigation strategies across multiple clinical settings including infectious disease care.
Mar 01, 2026
Researchers at Adelaide University found that salcaprozate sodium (SNAC), used in oral semaglutide formulations, was associated with gut bacteria changes, elevated inflammatory markers, and reduced brain-derived protein levels in a 21-day animal study.
Feb 26, 2026
Research initiatives are identifying novel therapeutic targets for Alzheimer's disease beyond traditional approaches, with focus on TREM2 agonists, metabolic interventions, and multi-omic data integration to diversify treatment strategies.
Feb 20, 2026
Researchers at Washington University School of Medicine developed a blood test-based method to predict when Alzheimer's symptoms will begin, with accuracy within three to four years, using plasma p-tau217 protein levels.
Feb 21, 2026
New research reveals semaglutide may directly repair cartilage in osteoarthritis patients, while a separate study raises concerns about SNAC, an ingredient used in oral semaglutide formulations, and its effects on gut health.
Feb 16, 2026
Blood-based biomarkers including brain-derived tau and amyloid-beta are enabling earlier Alzheimer's disease diagnosis through non-invasive testing, though confirmatory imaging remains necessary before treatment initiation.
Feb 18, 2026
A University of South Australia study finds salcaprozate sodium (SNAC), the compound enabling oral semaglutide tablets to work, may alter gut bacteria and increase inflammatory markers in rats, though human effects remain unclear.
